Ligand Pharmaceuticals (NASDAQ:LGND) had its target price lowered by Roth Capital from to in a report released on Monday morning, The Fly reports. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other equities research analysts have also commented on LGND. HC Wainwright reaffirmed a buy rating and set a $214.00 price target on shares of Ligand Pharmaceuticals in a research report on Thursday, January 16th. Benchmark started coverage on Ligand Pharmaceuticals in a research report on Thursday, February 6th. They set a buy rating and a $135.00 price target on the stock. ValuEngine raised Ligand Pharmaceuticals from a hold rating to a buy rating in a research report on Saturday, February 1st. Finally, BidaskClub lowered Ligand Pharmaceuticals from a sell rating to a strong sell rating in a research report on Thursday, January 16th. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $153.17.
Ligand Pharmaceuticals stock opened at $95.11 on Monday. The company has a debt-to-equity ratio of 0.85, a current ratio of 66.09 and a quick ratio of 65.66. The stock has a fifty day moving average price of $94.89 and a two-hundred day moving average price of $100.41. Ligand Pharmaceuticals has a 52-week low of $84.45 and a 52-week high of $130.50. The firm has a market capitalization of $1.68 billion, a P/E ratio of 3.24, a P/E/G ratio of 2.71 and a beta of 1.32.
Ligand Pharmaceuticals (NASDAQ:LGND) last released its quarterly earnings data on Thursday, February 6th. The biotechnology company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.07. Ligand Pharmaceuticals had a return on equity of 4.34% and a net margin of 523.19%. The firm had revenue of $27.00 million during the quarter, compared to analyst estimates of $25.30 million. During the same period in the prior year, the company posted $1.70 earnings per share. The business’s revenue for the quarter was down 54.7% compared to the same quarter last year. On average, equities research analysts predict that Ligand Pharmaceuticals will post 2.37 EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the stock. Quest Capital Management Inc. ADV acquired a new stake in Ligand Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Ligand Pharmaceuticals by 1,763.6% during the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 410 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 388 shares during the period. First Mercantile Trust Co. boosted its stake in shares of Ligand Pharmaceuticals by 11.7% during the 3rd quarter. First Mercantile Trust Co. now owns 900 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 94 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Ligand Pharmaceuticals by 23.5% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 820 shares of the biotechnology company’s stock worth $95,000 after acquiring an additional 156 shares during the period. Finally, Nisa Investment Advisors LLC boosted its stake in shares of Ligand Pharmaceuticals by 960.0% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,060 shares of the biotechnology company’s stock worth $106,000 after acquiring an additional 960 shares during the period.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.
Featured Article: How to invest using market indexes
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.